The purpose of our study was to assess the safety and use of liver biopsy in this patient population. Methods: In total, 1700 bone marrow transplants were performed at our institution from June ...

Many of these patients also have hyperlipidemia and ... and iron-study abnormalities. The liver can be assessed via ultrasound or CT to look for tumors; biopsy is reserved for definitive diagnosis ...

This Review summarizes current understanding of NAFLD, the evaluation of patients ... mellitus, hyperlipidemia and obesity. In response to the disadvantages of liver biopsy discussed above ...

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more ...

Although all patients with NAFLD need aggressive management of cardiovascular risk factors, it is only patients with NASH who need treatment targeted at the liver disease. None of the currently ...

As NAFLD can be considered a liver manifestation of the metabolic syndrome, its prevalence is high in obese people and in patients who ... or diabetes and hyperlipidemia—as no specific liver ...

Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. This study aimed to investigate ...

Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. This study aimed to investigate ...

Agile scores had the highest predictive value and classified fewer patients ... associated steatotic liver disease and “may be suitable alternatives” to routine liver biopsy.

Of these patients, liver biopsy was performed in 154 patients at 36 weeks and in 134 patients at 96 weeks. At 36 weeks, a reduction in fibrosis without worsening of MASH occurred in 8 of 61 ...